Patents by Inventor Tugrul T. Kararli
Tugrul T. Kararli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7695736Abstract: A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically effective total amount constituting about 30% to about 90% by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the composition. The composition is reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution. A lyophilization process is provided for preparation of such a composition.Type: GrantFiled: April 1, 2002Date of Patent: April 13, 2010Assignee: Pfizer Inc.Inventors: Tugrul T. Kararli, Sandeep Nema, Aziz Karim
-
Patent number: 7220867Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.Type: GrantFiled: July 26, 2005Date of Patent: May 22, 2007Assignee: Pharmacia Corporation (of Pfizer, Inc.)Inventors: Michael J. Hageman, Xiaorong He, Tugrul T. Kararli, Lesley A. MacKin, Patricia J. Miyake, Brian R. Rohrs, Kevin J. Stefanski
-
Patent number: 7172769Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particle, about 25% to 100% by weight of which are smaller than 1 ?m. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.Type: GrantFiled: December 6, 2000Date of Patent: February 6, 2007Assignee: Pharmacia CorporationInventors: Tugrul T. Kararli, Mark J. Kontny, Subhash Desai, Michael J. Hageman, Royal J. Haskell
-
Patent number: 6964978Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.Type: GrantFiled: December 6, 2000Date of Patent: November 15, 2005Assignee: Pharmacia CorporationInventors: Michael J. Hageman, Xiaorong He, Tugrul T. Kararli, Lesley A. Mackin, Patricia J. Miyake, Brian R. Rohrs, Kevin J. Stefanski
-
Publication number: 20040265382Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particle, about 25% to 100% by weight of which are smaller tban 1 &mgr;m. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.Type: ApplicationFiled: July 30, 2002Publication date: December 30, 2004Inventors: Tugrul T. Kararli, Mark J. Kontny, Subhash Desai, Michael J. Hageman, Royal J. Haskell
-
Publication number: 20040058926Abstract: The present invention provides methods for the treatment and prevention of ocular COX-2 mediated disorders using COX-2 inhibitors.Type: ApplicationFiled: September 22, 2003Publication date: March 25, 2004Inventors: Rebanta Bandyopadhyay, David Eveleth, Tom Van Haarlem, Tugrul T Kararli, Satish K. Singh
-
Publication number: 20030078266Abstract: A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically effective total amount constituting about 30% to about 90% by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the composition. The composition is reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution. A lyophilization process is provided for preparation of such a composition.Type: ApplicationFiled: April 1, 2002Publication date: April 24, 2003Inventors: Tugrul T. Kararli, Sandeep Nema, Aziz Karim
-
Publication number: 20030064098Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particles, about 25% to 100% by weight of which are smaller than 1 &mgr;m. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.Type: ApplicationFiled: June 5, 2001Publication date: April 3, 2003Inventors: Tugrul T. Kararli, Mark J. Kontny, Subhash Desai, Michael J. Hageman, Royal J. Haskell, Fred Hassan, James C. Forbes
-
Publication number: 20020142045Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particles, about 25% to 100% by weight of which are smaller than 1 &mgr;m. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.Type: ApplicationFiled: April 1, 2002Publication date: October 3, 2002Inventors: Tugrul T. Kararli, Mark J. Kontny, Subhash Desai, Michael J. Hageman, Royal J. Haskell, Fred Hassan, James C. Forbes
-
Publication number: 20020128267Abstract: The present invention provides methods for the treatment and prevention of ocular COX-2 mediated disorders using COX-2 inhibitors.Type: ApplicationFiled: May 4, 2001Publication date: September 12, 2002Inventors: Rebanta Bandyopadhyay, David Eveleth, Thomas Joseph Van Haarlem, Tugrul T. Kararli, Satish K. Singh
-
Publication number: 20020119193Abstract: A process is provided for preparing an oral fast-melt composition of a selective cyclooxygenase-2 inhibitory drug, the process comprising (a) a step of wet granulating the drug together with a binding agent comprising a saccharide of high moldability, and (b) a step of blending with the drug a saccharide of low moldability, wherein the above steps (a) and (b) occur in any order or simultaneously to result in formation of granules. The process optionally incorporates means to inhibit agglomeration of the drug, for example addition of a wetting agent. Optionally the process further comprises (c) a step of blending the granules with at least one of a lubricant, a sweetening agent and a flavoring agent to form a tableting blend, and (d) a step of compressing the tableting blend to form oral fast-melt tablets. Also provided is a composition prepared by such a process.Type: ApplicationFiled: August 17, 2001Publication date: August 29, 2002Inventors: Trang T. Le, Tugrul T. Kararli, Mark J. Kontny, Srikonda V. Sastry, Janaki R. Nyshadham, Arthur J. Pagliero
-
Publication number: 20020107250Abstract: An orally deliverable pharmaceutical composition is provided comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, and a glycol ether, for example diethylene glycol monoethyl ether. At least a substantial part of the drug is in dissolved or solubilized form in a solvent liquid comprising the glycol ether. The composition has rapid-onset properties and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders, particularly pain. For relief of pain in headache or migraine, the composition can optionally be administered together with a vasodilator.Type: ApplicationFiled: April 17, 2001Publication date: August 8, 2002Inventors: Madhusudan Hariharan, Tugrul T. Kararli, Fred Hassan, James C. Forbes
-
Publication number: 20020071857Abstract: A molded article such as a tablet is provided for administration to an oral cavity of a subject to treat or prevent a cyclooxygenase-2 mediated condition, disorder or disease. The molded article comprises a moldable blend of a therapeutically effective amount of a selective cyclooxygenase-2 inhibitory drug with a pharmaceutically acceptable excipient carrier system consisting predominantly of one or more carbohydrates, wherein ingredients and amounts thereof in the molded article and a process for preparing the molded article are selected such that the molded article exhibits rapid disintegration in the oral cavity, and wherein the moldable blend is prepared by a process step not requiring wet granulation.Type: ApplicationFiled: August 17, 2001Publication date: June 13, 2002Inventors: Tugrul T. Kararli, Mark J. Kontny, Trang T. Le
-
Publication number: 20020049233Abstract: A process is provided for preparing an oral fast-melt composition of a selective cyclooxygenase-2 inhibitory drug comprising (a) a step of wet granulating the selective cyclooxygenase-2 inhibitory drug together with a binding agent selected from gums, polypeptides, natural and modified starches, cellulosic materials, alginic acid and salts thereof, polyethylene glycol, polyvinylpyrrolidone, polymethacrylates, silicate salts and bentonites, and (b) a step of blending with the drug a saccharide of low moldability, wherein the above steps (a) and (b) occur in any order or simultaneously to result in formation of granules. Optionally the process further comprises (c) a step of blending the granules with at least one of a lubricant, a sweetening agent and a flavoring agent to form a tableting blend, and (d) a step of compressing the tableting blend to form oral fast-melt tablets. Also provided is a composition prepared by such a process.Type: ApplicationFiled: August 17, 2001Publication date: April 25, 2002Inventors: Tugrul T. Kararli, Mark J. Kontny, Trang T. Le
-
Publication number: 20020035264Abstract: There is provided a pharmaceutical composition suitable for topical administration to an eye which contains a selective COX-2 inhibitory drug or nanoparticles of a drug of low water solubility, in a concentration effective for treatment and/or prophylaxis of a disorder in the eye, and one or more ophthalmically acceptable excipients that reduce rate of removal from the eye such that the composition has an effective residence time of about 2 to about 24 hours. Also provided is a method of treating and/or preventing a disorder in an eye, the method comprising administering to the eye a composition of the invention.Type: ApplicationFiled: July 12, 2001Publication date: March 21, 2002Inventors: Tugrul T. Kararli, Rebanta Bandyopadhyay, Satish K. Singh, Leslie C. Hawley
-
Publication number: 20020006951Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.Type: ApplicationFiled: December 6, 2000Publication date: January 17, 2002Inventors: Michael J. Hageman, Xiaorong He, Tugrul T. Kararli, Lesley A. Mackin, Patricia J. Miyake, Brian R. Rohrs, Kevin J. Stefanski
-
Patent number: 5935939Abstract: The present invention provides for stabilization of misoprostol in solid dispersions using amorphous excipients or excipients which have been converted to an amorphous state such as hydroxypropyl cellulose, methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, cellulose acetate phthalate, cellulose acetate butyrate, hydroxyethyl cellulose, ethyl cellulose, polyvinyl alcohol, polyethylene glycol, starch, polypropylene, dextrans, dextrins, hydroxypropyl .beta.-cyclodextrin chitosan, co-(lactic/glycolic)copolymers, poly(orthoester), polyvinyl chloride, polyvinyl acetate, ethylene vinyl acetate, lectins, carbopols, silicon elastomers, cyclodextrins, polyacrylic polymers, maltodextrins, lactose, fructose, inositol, trehalose, maltose, and raffinose, (and other mono-, di- and tri- saccharides) and .alpha.-, .beta.- and .gamma.-cyclodextrins, and more preferably the excipients which are used are dextran, maltodextrin, hydroxypropyl .beta.-cyclodextrin and maltose.Type: GrantFiled: September 9, 1996Date of Patent: August 10, 1999Assignee: G. D. Searle & Co.Inventors: Tugrul T. Kararli, David Otto, Stanley C. Penzotti, Jr., James E. Truelove
-
Patent number: 5230897Abstract: Pharmaceutical compositions and transdermal patches comprised of pentamidine and a penetration enhancing amount of a terpene selected from the group consisting of menthol, carvone, carveol, dihydrocarveol, dihydrocarvone, neomenthol, isopulegol, terpene-4-ol, menthone, pulegol, camphor, geraniol, .alpha.-terpineol, citral, linalol, carvacrol, thymol and anethole are disclosed for delivery of a therapeutically effective amount of pentamidine or its pharmaceutically acceptable salts.Type: GrantFiled: October 31, 1991Date of Patent: July 27, 1993Assignee: G. D. Searle & Co.Inventors: Martin J. Griffin, Tugrul T. Kararli, Stanley C. Penzotti, Jr., Rachelle M. Rydzik, Cynthia M. Schmidt
-
Patent number: 5213807Abstract: A pharmaceutical composition includes a core of an NSAID selected from ibuprofen and ibuprofen salts, which core is surrounded by an intermediate coating impermeable to the passage of ibuprofen and a mantle coating which includes a prostaglandin surrounding the coated ibuprofen core.Type: GrantFiled: February 26, 1991Date of Patent: May 25, 1993Inventors: Pramod B. Chemburkar, Bahram Farhadieh, Barbara J. Struthers, Tugrul T. Kararli, Steven C. Schumann